Regenerative Medicine News

May 16, 2017 – (Asymmetrex) – Stem cell medicine biotechnology start-up Asymmetrex will present its new contract service for adult tissue stem cell counting applications to company representatives attending Cell & Gene Exchange 2017. CGX17, the first partnering conference organized by the Alliance for Regenerative Medicine, will be attended by stem cell therapy, gene therapy, gene editing, and pharmaceutical companies, all who would benefit from Asymmetrex’s technology for counting adult tissue stem cells.
April 20, 2017 – (uniQure) – "The decision to not pursue marketing authorization renewal of Glybera in Europe involved a thoughtful and careful evaluation of patient needs and the clinical use of the therapy, and is not related to any risk-benefit concern," stated Matthew Kapusta, chief executive officer of uniQure.  "Glybera's usage has been extremely limited and we do not envision patient demand increasing materially in the years ahead."
April 11, 2017 – (Organovo) – Organovo’s board of directors has appointed Taylor J. Crouch, previously CEO of eStudySite to succeed Keith Murphy as CEO.  Mr. Murphy will remain chairman of the board, and will serve as an advisor to the Company to ensure a seamless transition and offer his counsel and expertise.
April 10, 2017 – (Mesoblast) – Mesoblast Limited (ASX: MSB; Nasdaq: MESO) announced that the Phase 3 trial of its allogeneic mesenchymal precursor cell product candidate MPC-150-IM in patients with moderate to advanced chronic heart failure was successful in the pre-specified interim futility analysis of the efficacy endpoint in the trial's first 270 patients. It is expected that the trial will enroll in total approximately 600 patients. 
April 6, 2017 – (Mesoblast) – The funds were provided to Mesoblast under the Government's R&D Tax Incentive Program, which is designed to support industry innovation.
April 4, 2017 – (NantKwest) – Viracta will use funds from the Series B financing to support the advancement of VRx-3996 into Phase 2 clinical studies for the treatment of Epstein Barr Virus-associated malignancies via Viracta’s proprietary viral gene activation therapeutic approach.
April 4, 2017 – (Sentien) – The Series A round will be used to fund initial clinical development of Sentien’s SBI- 101 for the treatment of acute kidney injury.

Pages